Cardiac fibroblast activation and hyaluronan synthesis in response to hyperglycemia and diet-induced insulin resistance
- PMID: 30755628
- PMCID: PMC6372628
- DOI: 10.1038/s41598-018-36140-6
Cardiac fibroblast activation and hyaluronan synthesis in response to hyperglycemia and diet-induced insulin resistance
Abstract
Diabetic patients are at a greater risk of heart failure due to diabetic cardiomyopathy and worsened outcome post-myocardial infarction. While the molecular mechanisms remain unclear, fibrosis and chronic inflammation are common characteristics of both conditions. Diabetes mellitus (types I and II) results in excessive hyaluronan (HA) deposition in vivo, and hyperglycemia stimulates HA synthesis for several cell types in vitro. HA-rich extracellular matrix contributes to fibrotic, hyperplastic and inflammatory disease progression. We hypothesized that excessive hyperglycemia-driven HA accumulation may contribute to pathological fibroblast activation and fibrotic remodelling in diabetic patients. Therefore, we analysed the impact of both hyperglycemia and diet-induced obesity and insulin resistance on HA matrix formation and cardiac fibroblast activation. Here we report that cardiac fibroblasts isolated from mice on a diabetogenic diet acquire pro-fibrotic gene expression without a concomitant increase in HA matrix deposition. Additionally, hyperglycemia alone does not stimulate HA synthesis or cardiac fibroblast activation in vitro, suggesting that the direct effect of hyperglycemia on fibroblasts is not the primary driver of fibrotic remodelling in cardiac diabetic maladaptation.
Conflict of interest statement
The authors declare no competing interests.
Figures






Similar articles
-
Inhibition of MEF2A prevents hyperglycemia-induced extracellular matrix accumulation by blocking Akt and TGF-β1/Smad activation in cardiac fibroblasts.Int J Biochem Cell Biol. 2015 Dec;69:52-61. doi: 10.1016/j.biocel.2015.10.012. Epub 2015 Oct 23. Int J Biochem Cell Biol. 2015. PMID: 26482596
-
Targeted inhibition of calpain reduces myocardial hypertrophy and fibrosis in mouse models of type 1 diabetes.Diabetes. 2011 Nov;60(11):2985-94. doi: 10.2337/db10-1333. Epub 2011 Sep 12. Diabetes. 2011. PMID: 21911754 Free PMC article.
-
Limiting extracellular matrix expansion in diet-induced obese mice reduces cardiac insulin resistance and prevents myocardial remodelling.Mol Metab. 2024 Aug;86:101970. doi: 10.1016/j.molmet.2024.101970. Epub 2024 Jun 20. Mol Metab. 2024. PMID: 38908792 Free PMC article.
-
Hyaluronan's Role in Fibrosis: A Pathogenic Factor or a Passive Player?Biomed Res Int. 2015;2015:790203. doi: 10.1155/2015/790203. Epub 2015 Oct 25. Biomed Res Int. 2015. PMID: 26583132 Free PMC article. Review.
-
Diabetic fibrosis.Biochim Biophys Acta Mol Basis Dis. 2021 Apr 1;1867(4):166044. doi: 10.1016/j.bbadis.2020.166044. Epub 2020 Dec 28. Biochim Biophys Acta Mol Basis Dis. 2021. PMID: 33378699 Free PMC article. Review.
Cited by
-
RIPK1-RIPK3 mediates myocardial fibrosis in type 2 diabetes mellitus by impairing autophagic flux of cardiac fibroblasts.Cell Death Dis. 2022 Feb 14;13(2):147. doi: 10.1038/s41419-022-04587-1. Cell Death Dis. 2022. PMID: 35165268 Free PMC article.
-
Investigating Celastrol's Anti-DCM Targets and Mechanisms via Network Pharmacology and Experimental Validation.Biomed Res Int. 2022 Jul 5;2022:7382130. doi: 10.1155/2022/7382130. eCollection 2022. Biomed Res Int. 2022. Retraction in: Biomed Res Int. 2023 Dec 29;2023:9874346. doi: 10.1155/2023/9874346. PMID: 35845929 Free PMC article. Retracted.
-
The Diabetic Cardiomyopathy: The Contributing Pathophysiological Mechanisms.Front Med (Lausanne). 2021 Jun 30;8:695792. doi: 10.3389/fmed.2021.695792. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34277669 Free PMC article. Review.
-
Glucose transporters in cardiovascular system in health and disease.Pflugers Arch. 2020 Sep;472(9):1385-1399. doi: 10.1007/s00424-020-02444-8. Epub 2020 Aug 18. Pflugers Arch. 2020. PMID: 32809061 Review.
-
Fibrosis of the diabetic heart: Clinical significance, molecular mechanisms, and therapeutic opportunities.Adv Drug Deliv Rev. 2021 Sep;176:113904. doi: 10.1016/j.addr.2021.113904. Epub 2021 Jul 29. Adv Drug Deliv Rev. 2021. PMID: 34331987 Free PMC article. Review.
References
-
- Cavender MA, et al. Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and Death: Outcomes at 4 Years From the Reduction of Atherothrombosis for Continued Health (REACH) Registry. Circulation. 2015;132:923–931. doi: 10.1161/circulationaha.114.014796. - DOI - PubMed
-
- MacDonald MR, et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J. 2008;29:1377–1385. doi: 10.1093/eurheartj/ehn153. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical